Pharmaceuticals company Cohance Lifesciences announced Q1FY26 results Company reported revenue of Rs 5,493 million, up 13% YoY growth exceeds 25%. Gross margins expanded to 73.0% from 68.4% in Q1FY25. EBITDA was Rs 1,314 million with a margin of 23.9%. Vivek Sharma, Executive Chairman, said: "Q1FY26 has been an important start to the year, with progress not just in execution but in strengthening the foundation we have built. Our growing presence in niche modalities like ADCs and oligonucleotides, combined with a deepening global customer base, positions Cohance for accelerated growth. With strengthened leadership and the guidance of our External Advisory Board, we remain committed to becoming a global technology-led CDMO, delivering long-term value for all stakeholders." Result PDF